董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Tsur | 男 | Director | 75 | 67.30万美元 | 65.69 | 2026-03-11 |
| Lilach Asher Topilsky | 女 | Chair of the Board | 55 | 未披露 | 4.90 | 2026-03-11 |
| Karnit Goldwasser | 女 | Director | 49 | 未披露 | 4.90 | 2026-03-11 |
| Lilach Payorski | 女 | Director | 52 | 未披露 | 2.25 | 2026-03-11 |
| Uri Botzer | 男 | Director | 37 | 未披露 | 2.25 | 2026-03-11 |
| Benjamin Dekel | 男 | External Director | 59 | 未披露 | 0.80 | 2026-03-11 |
| Assaf Itshayek | 男 | External Director | 54 | 未披露 | 0.80 | 2026-03-11 |
| Leon Recanati | 男 | Director | 77 | 未披露 | 348.19 | 2026-03-11 |
| Ishay Davidi | 男 | Director | 64 | 未披露 | 2213.33 | 2026-03-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yael Brenner | 女 | Vice President, Quality | 62 | 未披露 | 6.63 | 2026-03-11 |
| Orit Pinchuk | 女 | Vice President, Regulatory Affairs and PVG | 60 | 31.94万美元 | 2.71 | 2026-03-11 |
| Chaime Orlev | 男 | Chief Financial Officer | 55 | 59.30万美元 | 7.91 | 2026-03-11 |
| Eran Nir | 男 | Chief Operating Officer | 53 | 51.20万美元 | 3.29 | 2026-03-11 |
| Liron Reshef | 女 | Vice President, Human Resources | 55 | 未披露 | 3.00 | 2026-03-11 |
| Hanni Neheman | 女 | Vice President, Marketing & Sales | 56 | 未披露 | 1.84 | 2026-03-11 |
| Boris Gorelik | 男 | Vice President, Business Development and Strategic Programs | 45 | 45.70万美元 | 6.00 | 2026-03-11 |
| Nir Livneh | 男 | Corporate Secretary and General Counsel and Vice President | 47 | 未披露 | 2.95 | 2026-03-11 |
| Shavit Beladev | 女 | Vice President, Plasma Operations | 55 | 未披露 | 1.84 | 2026-03-11 |
| Jon Knight | 男 | Vice President, U.S. Commercial Operations | 60 | 34.00万美元 | 6.00 | 2026-03-11 |
| Amir London | 男 | Chief Executive Officer | 57 | 81.90万美元 | 36.19 | 2026-03-11 |
董事简历
中英对照 | 中文 | 英文- David Tsur
-
David Tsur是Kamada有限公司（“纳斯达克”）的联合创始人，该公司是一家在TERM3和特拉维夫证券交易所上市的上市公司。自Kamada成立以来至2015年担任首席执行官及董事会成员，并于2015年7月至2019年12月担任Kamada董事会副主席。自2021年2月起，他还担任伦敦证券交易所（LSE）上市公司Kanabo Group PLC（“Kanabo”）的董事长。Tsur先生此前曾于2016年至2021年担任TASE和OTC上市公司Collplant有限公司的董事会主席。Tsur先生还曾在以色列经济和工业部（前以色列工业和贸易部）担任过多个职位，包括阿根廷和伊朗的首席经济学家和商务专员。Tsur先生拥有以色列耶路撒冷希伯来大学的文学、经济学和国际关系学士学位和工商管理硕士学位（1976年）。
David Tsur has served on board of directors since inception and serves as a member of Strategy Committee. Mr. Tsur served as the Active Deputy Chairman on a half time basis from July 2015 until December 31, 2019. Mr. Tsur served as Chief Executive Officer from inception until July 2015. Mr. Tsur served as the Chairman of the Board of Directors of Kanabo Ltd. (LSE) from 2018 to 2024 and as a director of BioHarvest Sciences Inc. (CSE) from 2022 to 2025. Prior to co founding Kamada in 1990, Mr. Tsur served as Chief Executive Officer of Arad Systems and RAD Chemicals Inc. Mr. Tsur previoly served as the Chairman of the Board of Directors of CollPlant Ltd., a company listed on the TASE and OTC market. Mr. Tsur has also held vario positions in the Israeli Ministry of Economy and Indtry (formerly named the Ministry of Indtry and Trade), including Chief Economist and Commercial Attaché in Argentina and Iran. Mr. Tsur received the 2024 Lifetime Achievement Award by the Manufacturers Association of Israel for his many years of contribution to the Israeli biopharmaceutical indtry. Mr. Tsur holds a B.A. degree in Economics and International Relations and an M.B.A. degree in Biness Management, both from the Hebrew University of Jeralem. - David Tsur是Kamada有限公司（“纳斯达克”）的联合创始人，该公司是一家在TERM3和特拉维夫证券交易所上市的上市公司。自Kamada成立以来至2015年担任首席执行官及董事会成员，并于2015年7月至2019年12月担任Kamada董事会副主席。自2021年2月起，他还担任伦敦证券交易所（LSE）上市公司Kanabo Group PLC（“Kanabo”）的董事长。Tsur先生此前曾于2016年至2021年担任TASE和OTC上市公司Collplant有限公司的董事会主席。Tsur先生还曾在以色列经济和工业部（前以色列工业和贸易部）担任过多个职位，包括阿根廷和伊朗的首席经济学家和商务专员。Tsur先生拥有以色列耶路撒冷希伯来大学的文学、经济学和国际关系学士学位和工商管理硕士学位（1976年）。
- David Tsur has served on board of directors since inception and serves as a member of Strategy Committee. Mr. Tsur served as the Active Deputy Chairman on a half time basis from July 2015 until December 31, 2019. Mr. Tsur served as Chief Executive Officer from inception until July 2015. Mr. Tsur served as the Chairman of the Board of Directors of Kanabo Ltd. (LSE) from 2018 to 2024 and as a director of BioHarvest Sciences Inc. (CSE) from 2022 to 2025. Prior to co founding Kamada in 1990, Mr. Tsur served as Chief Executive Officer of Arad Systems and RAD Chemicals Inc. Mr. Tsur previoly served as the Chairman of the Board of Directors of CollPlant Ltd., a company listed on the TASE and OTC market. Mr. Tsur has also held vario positions in the Israeli Ministry of Economy and Indtry (formerly named the Ministry of Indtry and Trade), including Chief Economist and Commercial Attaché in Argentina and Iran. Mr. Tsur received the 2024 Lifetime Achievement Award by the Manufacturers Association of Israel for his many years of contribution to the Israeli biopharmaceutical indtry. Mr. Tsur holds a B.A. degree in Economics and International Relations and an M.B.A. degree in Biness Management, both from the Hebrew University of Jeralem.
- Lilach Asher Topilsky
-
Lilach Asher Topilsky自2019年12月起担任我们的董事会成员。截至2019年12月，Topilsky女士是以色列最大的私募股权基金FIMI Opportunity Funds的高级合伙人。在2019年11月底之前，Asher Topilsky女士曾担任以色列领先的银行集团之一以色列折扣银行TASE的总裁兼首席执行官，IDBNY Bankcorp的董事长和IDB Bank New York的董事。2014年2月以来。Asher Topilsky女士还于2014年至2016年担任Mercantile Bank的董事长。Asher Topilsky女士目前担任G1Ltd.（TASE）的董事会主席和特拉维夫大学（Tel Aviv University）的董事。加入Israel Discount Bank之前，Asher Toplisky女士曾担任Bank Hapoalim（TASE）的管理层成员，担任副首席执行官兼零售银行部门主管（2009年至2013年）和战略与规划部主管（2007年至2009年）。Asher Topilsky女士还担任波士顿咨询集团（波士顿咨询集团，芝加哥，1997-1998年）和Shaldor战略咨询公司（以色列，1995-1996年）的战略顾问。Asher Topilsky女士拥有特拉维夫大学（Tel Aviv University）管理与经济学学士学位和美国芝加哥西北大学凯洛格管理学院（Kellogg School of Management）工商管理硕士学位。
Lilach Asher Topilsky has served as a member of board of directors since December 2019, as the Chair of board of directors since August 2020, served as a member of Compensation Committee from August 2020 until August 2023 and serves as a member of Strategy Committee (as the Chair of the Strategy Committee since November 2023). Ms. Asher Topilsky has been a Senior Partner in the FIMI Opportunity Funds, Israel's largest group of private equity funds, since December 2019. Ms. Asher Topilsky currently serves as the chair of the board of directors of Rimoni Indtries Ltd. (TASE), SOS Ltd. Elyakim Ben Ari Group Ltd., Amal and Beyond Ltd. and Marom Dolphin Ltd. and as a director at Amiad Water Systems Ltd. (AIM), Ashot Ashkelon Indtries Ltd. (TASE) and Tel Aviv University. Prior to joining FIMI, Ms. Asher Topilsky served as the President and CEO of Israel Discount Bank (TASE), one of the leading banking groups in Israel, as the Chairman at IDBNY BANKCORP and as a director at IDB Bank New York from 2014 – 2019. Ms. Asher Topilsky also served as the Chairman of Mercantile Bank from 2014 – 2016. Before that, Ms. Asher Topilsky served as a member of the management of Bank Hapoalim (TASE) as Deputy CEO & Head of Retail Banking Division (2009 – 2013) & Head of Strategy & Planning Division (2007 – 2009). Ms. Asher Topilsky served as a Strategy Consultant at The Boston Consulting Group (BCG, Chicago 1997 – 1998) and at Shaldor Strategy Consulting (Israel 1995 – 1996). Ms. Asher Topilsky holds an M.B.A. degree from Kellogg School of Management, Northstern University, Chicago, A (1997) and a B.A. degree in Management and Economics from Tel Aviv University, Israel (Magna Cum Laude, 1994). - Lilach Asher Topilsky自2019年12月起担任我们的董事会成员。截至2019年12月，Topilsky女士是以色列最大的私募股权基金FIMI Opportunity Funds的高级合伙人。在2019年11月底之前，Asher Topilsky女士曾担任以色列领先的银行集团之一以色列折扣银行TASE的总裁兼首席执行官，IDBNY Bankcorp的董事长和IDB Bank New York的董事。2014年2月以来。Asher Topilsky女士还于2014年至2016年担任Mercantile Bank的董事长。Asher Topilsky女士目前担任G1Ltd.（TASE）的董事会主席和特拉维夫大学（Tel Aviv University）的董事。加入Israel Discount Bank之前，Asher Toplisky女士曾担任Bank Hapoalim（TASE）的管理层成员，担任副首席执行官兼零售银行部门主管（2009年至2013年）和战略与规划部主管（2007年至2009年）。Asher Topilsky女士还担任波士顿咨询集团（波士顿咨询集团，芝加哥，1997-1998年）和Shaldor战略咨询公司（以色列，1995-1996年）的战略顾问。Asher Topilsky女士拥有特拉维夫大学（Tel Aviv University）管理与经济学学士学位和美国芝加哥西北大学凯洛格管理学院（Kellogg School of Management）工商管理硕士学位。
- Lilach Asher Topilsky has served as a member of board of directors since December 2019, as the Chair of board of directors since August 2020, served as a member of Compensation Committee from August 2020 until August 2023 and serves as a member of Strategy Committee (as the Chair of the Strategy Committee since November 2023). Ms. Asher Topilsky has been a Senior Partner in the FIMI Opportunity Funds, Israel's largest group of private equity funds, since December 2019. Ms. Asher Topilsky currently serves as the chair of the board of directors of Rimoni Indtries Ltd. (TASE), SOS Ltd. Elyakim Ben Ari Group Ltd., Amal and Beyond Ltd. and Marom Dolphin Ltd. and as a director at Amiad Water Systems Ltd. (AIM), Ashot Ashkelon Indtries Ltd. (TASE) and Tel Aviv University. Prior to joining FIMI, Ms. Asher Topilsky served as the President and CEO of Israel Discount Bank (TASE), one of the leading banking groups in Israel, as the Chairman at IDBNY BANKCORP and as a director at IDB Bank New York from 2014 – 2019. Ms. Asher Topilsky also served as the Chairman of Mercantile Bank from 2014 – 2016. Before that, Ms. Asher Topilsky served as a member of the management of Bank Hapoalim (TASE) as Deputy CEO & Head of Retail Banking Division (2009 – 2013) & Head of Strategy & Planning Division (2007 – 2009). Ms. Asher Topilsky served as a Strategy Consultant at The Boston Consulting Group (BCG, Chicago 1997 – 1998) and at Shaldor Strategy Consulting (Israel 1995 – 1996). Ms. Asher Topilsky holds an M.B.A. degree from Kellogg School of Management, Northstern University, Chicago, A (1997) and a B.A. degree in Management and Economics from Tel Aviv University, Israel (Magna Cum Laude, 1994).
- Karnit Goldwasser
-
Karnit Goldwasser自2019年12月起担任我们的董事会成员。Goldwasser女士担任各种机构和组织的独立顾问和环境工程师。Goldwasser女士自2017年9月起担任Orian DB Schenker Delek San Recycling Ltd.（自2016年12月起）和ELA Recycling Corporation（自2015年4月起）的董事。Goldwasser女士曾担任the Government-Owned Environmental Services Company Ltd.的董事，担任安全委员会主席（2010年至2016年），并担任特拉维夫-雅法市议会成员，持有环境投资组合（2013年至2016年）。Goldwasser女士还曾担任特拉维夫-贾法市几家公司的董事:Dan Municipal Environment Association，担任审计委员会主席；特拉维夫-贾法经济发展局；Ganei Yehoshua有限公司。Goldwasser女士拥有学士学位。环境工程学位，专注于化学、数学和环境工程，以及理学硕士学位。Technion-Israel Institute of Technology土木工程学位，专攻流体动力学和水资源，IDC Herzliya Lauder School of Government外交和战略公共政策和行政硕士学位。Goldwasser女士还完成了特拉维夫大学（Tel Aviv University）管理学院Lahav的董事课程。
Karnit Goldwasser has served on board of directors since December 2019 and served as a member of Audit Committee and Compensation Committee from January 2020 until Augt 2023. Ms. Goldwasser serves as an independent consultant and environmental engineer for vario agencies and organizations. Ms. Goldwasser is a director at Delek San Recycling Ltd. (since December 2016). Ms. Goldwasser previoly served as a director at ELA Recycling Corporation (2015 – September 2021), Orian DB Schenker (2017 – 2020) and at the government owned Environmental Services Company Ltd., as chair of the Safety Committee (2010 – 2016) and as a member of the Tel Aviv Jaffa City Council, holding the environmental portfolio (2013 – 2016). Ms. Goldwasser also served as a director in several Tel Aviv Jaffa municipality corporations: Dan Municipal Sanitation Association, as chair of the audit committee; Tel Aviv Jaffa Economic Development Authority; and Ganei Yehoshua Co. Ltd. Ms. Goldwasser holds a B.Sc. degree in Environmental Engineering, focing on chemistry, mathematics and environmental engineering, a M.Sc. degree in Civil Engineering, specializing in Hydrodynamics and Water Resces, both from the Technion — Israel Institute of Technology, and a M.A. degree in Public Policy and Administration from the Lauder School of Government, Diplomacy and Strategy, IDC Herzliya. Ms. Goldwasser also completed the Directors Program at LAHAV, School of Management, Tel Aviv University. - Karnit Goldwasser自2019年12月起担任我们的董事会成员。Goldwasser女士担任各种机构和组织的独立顾问和环境工程师。Goldwasser女士自2017年9月起担任Orian DB Schenker Delek San Recycling Ltd.（自2016年12月起）和ELA Recycling Corporation（自2015年4月起）的董事。Goldwasser女士曾担任the Government-Owned Environmental Services Company Ltd.的董事，担任安全委员会主席（2010年至2016年），并担任特拉维夫-雅法市议会成员，持有环境投资组合（2013年至2016年）。Goldwasser女士还曾担任特拉维夫-贾法市几家公司的董事:Dan Municipal Environment Association，担任审计委员会主席；特拉维夫-贾法经济发展局；Ganei Yehoshua有限公司。Goldwasser女士拥有学士学位。环境工程学位，专注于化学、数学和环境工程，以及理学硕士学位。Technion-Israel Institute of Technology土木工程学位，专攻流体动力学和水资源，IDC Herzliya Lauder School of Government外交和战略公共政策和行政硕士学位。Goldwasser女士还完成了特拉维夫大学（Tel Aviv University）管理学院Lahav的董事课程。
- Karnit Goldwasser has served on board of directors since December 2019 and served as a member of Audit Committee and Compensation Committee from January 2020 until Augt 2023. Ms. Goldwasser serves as an independent consultant and environmental engineer for vario agencies and organizations. Ms. Goldwasser is a director at Delek San Recycling Ltd. (since December 2016). Ms. Goldwasser previoly served as a director at ELA Recycling Corporation (2015 – September 2021), Orian DB Schenker (2017 – 2020) and at the government owned Environmental Services Company Ltd., as chair of the Safety Committee (2010 – 2016) and as a member of the Tel Aviv Jaffa City Council, holding the environmental portfolio (2013 – 2016). Ms. Goldwasser also served as a director in several Tel Aviv Jaffa municipality corporations: Dan Municipal Sanitation Association, as chair of the audit committee; Tel Aviv Jaffa Economic Development Authority; and Ganei Yehoshua Co. Ltd. Ms. Goldwasser holds a B.Sc. degree in Environmental Engineering, focing on chemistry, mathematics and environmental engineering, a M.Sc. degree in Civil Engineering, specializing in Hydrodynamics and Water Resces, both from the Technion — Israel Institute of Technology, and a M.A. degree in Public Policy and Administration from the Lauder School of Government, Diplomacy and Strategy, IDC Herzliya. Ms. Goldwasser also completed the Directors Program at LAHAV, School of Management, Tel Aviv University.
- Lilach Payorski
-
自2022年3月起担任Oddity Tech Ltd.董事会成员，并拟根据《公司法》担任外部董事，但须在本次发行后三个月内获得Oddity Tech Ltd.股东批准，方可当选为外部董事。Payorski女士目前担任Kamada有限公司和Scodix有限公司的董事兼审计委员会主席和薪酬委员会成员。Payorski女士还于2017年1月至2022年2月担任3D打印机和添加剂解决方案开发商和制造商Stratasys Ltd.的首席财务官。在此之前，Payorski女士于2012年12月至2016年12月担任Stratasys Ltd.公司财务高级副总裁。Payorski女士拥有特拉维夫大学会计和经济学学士学位。Payorski女士还完成了特拉维夫大学管理学院LAHAV的董事会和高级公司官员课程。
Lilach Payorski has served as a member of board of directors since March 2022; she chairs the Audit Committee and is classified as an external director under the Companies Law. Ms. Payorski currently serves as director and member of the audit and compensation committees of Kamada Ltd. Ms. Payorski also served as the chief financial officer of Stratasys Ltd., a developer and manufacturer of 3D printers and additive solutions, from January 2017 to February 2022. Prior to that, from December 2012 until December 2016, Ms. Payorski served as Senior Vice President, Corporate Finance at Stratasys Ltd. Ms. She previoly held key finance management positions with PMC Sierra Inc (NASDAQ: PMC), Checkpoint Software Technologies (NASDAQ:CHKP), WindRiver Systems (NASDAQ:WIND), and Ernst & Young. Payorski holds a B.A. in Accounting and Economics from Tel Aviv University. Ms. Payorski also completed the Board of Directors and Senior Corporate Officers Program at LAHAV, School of Management, Tel Aviv University. - 自2022年3月起担任Oddity Tech Ltd.董事会成员，并拟根据《公司法》担任外部董事，但须在本次发行后三个月内获得Oddity Tech Ltd.股东批准，方可当选为外部董事。Payorski女士目前担任Kamada有限公司和Scodix有限公司的董事兼审计委员会主席和薪酬委员会成员。Payorski女士还于2017年1月至2022年2月担任3D打印机和添加剂解决方案开发商和制造商Stratasys Ltd.的首席财务官。在此之前，Payorski女士于2012年12月至2016年12月担任Stratasys Ltd.公司财务高级副总裁。Payorski女士拥有特拉维夫大学会计和经济学学士学位。Payorski女士还完成了特拉维夫大学管理学院LAHAV的董事会和高级公司官员课程。
- Lilach Payorski has served as a member of board of directors since March 2022; she chairs the Audit Committee and is classified as an external director under the Companies Law. Ms. Payorski currently serves as director and member of the audit and compensation committees of Kamada Ltd. Ms. Payorski also served as the chief financial officer of Stratasys Ltd., a developer and manufacturer of 3D printers and additive solutions, from January 2017 to February 2022. Prior to that, from December 2012 until December 2016, Ms. Payorski served as Senior Vice President, Corporate Finance at Stratasys Ltd. Ms. She previoly held key finance management positions with PMC Sierra Inc (NASDAQ: PMC), Checkpoint Software Technologies (NASDAQ:CHKP), WindRiver Systems (NASDAQ:WIND), and Ernst & Young. Payorski holds a B.A. in Accounting and Economics from Tel Aviv University. Ms. Payorski also completed the Board of Directors and Senior Corporate Officers Program at LAHAV, School of Management, Tel Aviv University.
- Uri Botzer
-
Uri Botzer自2022年12月起担任董事会成员，并担任战略委员会成员。自2019年以来，Botzer先生一直是以色列最大的私募股权基金集团FIMI Opportunity Funds的合伙人。Botzer先生目前在Marom Dolphin Ltd.和Simplivia Healthcare Ltd.担任董事。在加入FIMI之前，Botzer先生曾在Fischer（FBC & Co.）担任律师。Botzer先生拥有Biness Administration学士学位和法学学士学位。（法学学士），优等生，赫兹利亚Reichman大学。
Uri Botzer has served as a member of board of directors since December 2022 and serves as a member of Strategy Committee. Mr. Botzer has been a Partner in the FIMI Opportunity Funds, Israel's largest group of private equity funds, since 2019. Mr. Botzer currently serves as a director at Marom Dolphin Ltd. and Simplivia Healthcare Ltd. Prior to joining FIMI, Mr. Botzer served as a lawyer at FISCHER (FBC & Co.). Mr. Botzer holds a B.A. degree in Biness Administration and a LL.B. (Bachelor of Law), Cum Laude, from Reichman University, Herzliya. - Uri Botzer自2022年12月起担任董事会成员，并担任战略委员会成员。自2019年以来，Botzer先生一直是以色列最大的私募股权基金集团FIMI Opportunity Funds的合伙人。Botzer先生目前在Marom Dolphin Ltd.和Simplivia Healthcare Ltd.担任董事。在加入FIMI之前，Botzer先生曾在Fischer（FBC & Co.）担任律师。Botzer先生拥有Biness Administration学士学位和法学学士学位。（法学学士），优等生，赫兹利亚Reichman大学。
- Uri Botzer has served as a member of board of directors since December 2022 and serves as a member of Strategy Committee. Mr. Botzer has been a Partner in the FIMI Opportunity Funds, Israel's largest group of private equity funds, since 2019. Mr. Botzer currently serves as a director at Marom Dolphin Ltd. and Simplivia Healthcare Ltd. Prior to joining FIMI, Mr. Botzer served as a lawyer at FISCHER (FBC & Co.). Mr. Botzer holds a B.A. degree in Biness Administration and a LL.B. (Bachelor of Law), Cum Laude, from Reichman University, Herzliya.
- Benjamin Dekel
-
Benjamin Dekel自2023年8月起担任外部董事（《公司法》所指），并担任审计委员会和薪酬委员会成员。Dekel教授目前担任RenoVate Biopharmaceuticals Ltd.的创始人和首席科学家，担任特拉维夫大学Sagol再生医学中心主任；担任特拉维夫大学医学院副院长；Sheba医学中心儿科肾脏病学和儿科干细胞研究所所长；担任以色列卫生部细胞和基因治疗高级委员会成员；并担任Stemrad，Ltd.科学顾问委员会成员。2009年6月至2020年6月，Dekel教授担任KidneyCure Inc.首席科学家和董事会成员。2011年，德克尔教授曾担任斯坦福大学访问学者。2003年1月至2005年1月，Dekel教授担任伊兹曼研究所研究员。Dekel教授拥有以色列理工学院（Technion — Israel Institute of Technology）的医学医学医学博士学位和伊兹曼研究所（izmann Institute）的免疫学与移植生物学博士学位。
Benjamin Dekel has served as an external director (within the meaning of the Companies Law) since Augt 2023 and serves as a member of Audit Committee and Compensation Committee. Prof. Dekel currently serves as the Founder and Chief Scientist of RenoVate Biopharmaceuticals Ltd., as director at Sagol Center for Regenerative Medicine, Tel Aviv University; as Vice Dean, School of Medicine, Tel Aviv University; Chief, Pediatric Nephrology and Pediatric Stem Cell Research Institute, Sheba Medical Center; as a member of the Higher Committee on Cell and Gene Therapy, Israel Ministry of Health; and as a member of the Scientific Advisory Board, Stemrad, Ltd. From June 2009 until June 2020, Prof. Dekel served as Chief Scientist and a member of the board of directors of KidneyCure Inc. In 2011, Prof. Dekel Served as a Visiting Scholar at Stanford University. From January 2003 to January 2005, Prof. Dekel Served as a Fellow at the izmann Institute. Prof. Dekel holds an MD degree in Medicine from the Technion — Israel Institute of Technology and a PhD in Immunology & Transplantation Biology from the izmann Institute. - Benjamin Dekel自2023年8月起担任外部董事（《公司法》所指），并担任审计委员会和薪酬委员会成员。Dekel教授目前担任RenoVate Biopharmaceuticals Ltd.的创始人和首席科学家，担任特拉维夫大学Sagol再生医学中心主任；担任特拉维夫大学医学院副院长；Sheba医学中心儿科肾脏病学和儿科干细胞研究所所长；担任以色列卫生部细胞和基因治疗高级委员会成员；并担任Stemrad，Ltd.科学顾问委员会成员。2009年6月至2020年6月，Dekel教授担任KidneyCure Inc.首席科学家和董事会成员。2011年，德克尔教授曾担任斯坦福大学访问学者。2003年1月至2005年1月，Dekel教授担任伊兹曼研究所研究员。Dekel教授拥有以色列理工学院（Technion — Israel Institute of Technology）的医学医学医学博士学位和伊兹曼研究所（izmann Institute）的免疫学与移植生物学博士学位。
- Benjamin Dekel has served as an external director (within the meaning of the Companies Law) since Augt 2023 and serves as a member of Audit Committee and Compensation Committee. Prof. Dekel currently serves as the Founder and Chief Scientist of RenoVate Biopharmaceuticals Ltd., as director at Sagol Center for Regenerative Medicine, Tel Aviv University; as Vice Dean, School of Medicine, Tel Aviv University; Chief, Pediatric Nephrology and Pediatric Stem Cell Research Institute, Sheba Medical Center; as a member of the Higher Committee on Cell and Gene Therapy, Israel Ministry of Health; and as a member of the Scientific Advisory Board, Stemrad, Ltd. From June 2009 until June 2020, Prof. Dekel served as Chief Scientist and a member of the board of directors of KidneyCure Inc. In 2011, Prof. Dekel Served as a Visiting Scholar at Stanford University. From January 2003 to January 2005, Prof. Dekel Served as a Fellow at the izmann Institute. Prof. Dekel holds an MD degree in Medicine from the Technion — Israel Institute of Technology and a PhD in Immunology & Transplantation Biology from the izmann Institute.
- Assaf Itshayek
-
Assaf Itshayek，2010年1月起，他担任我公司首席财务官。2009年6月加入公司起，他担任我公司前财政副总裁。加入公司之前，2006至2008年，他担任纳斯达克上市公司以色列的Metalink Ltd的公司财务长，准备与美国一般公认会计原则相一致的财务报告。在此之前，2005至2006年，他担任Deloitte Brightman Almagor & Co. 的高级审计经济，管理并审计高科技与工业公司，准备与美国一般公认会计原则相一致的财务报告。2007年，他在特拉维夫大学（Tel Aviv University）获得金融工商管理硕士学位；1999年，在The College for Management获得工商管理和会计学学士学位，目前是以色列的一名注册会计师。他已经从公司辞职，于2011年3月31日生效。
Assaf Itshayek has served as our Chief Financial Officer since January 2010. Mr. Itshayek was formerly our Vice President of Finance, which position he held since joining the Company in June 2009. Prior to joining the Company, Mr. Itshayek was a Corporate Controller at Metalink Ltd. in Israel, a NASDAQ listed company, from 2006 through 2008 where, among other things, he prepared financial statements in conformity with United States Generally Accepted Accounting Principles ("U.S. GAAP"). Prior to that, he was a Senior Audit Manager at Deloitte Brightman Almagor & Co. Certified Public Accountants in Israel from 2005 through 2006 where, among other things, he managed and audited high-tech and industrial companies, and prepared financial statements in conformity with U.S. GAAP. Mr. Itshayaek earned a Master of Business Administration in Financial Management from Tel Aviv University in 2007 he earned a Bachelor of Arts in Business Administration and Accountancy from The College for Management in 1999 and he is currently a licensed Certified Public Accountant in Israel. Mr. Itshayek has resigned from the Company, effective March 31 2011. - Assaf Itshayek，2010年1月起，他担任我公司首席财务官。2009年6月加入公司起，他担任我公司前财政副总裁。加入公司之前，2006至2008年，他担任纳斯达克上市公司以色列的Metalink Ltd的公司财务长，准备与美国一般公认会计原则相一致的财务报告。在此之前，2005至2006年，他担任Deloitte Brightman Almagor & Co. 的高级审计经济，管理并审计高科技与工业公司，准备与美国一般公认会计原则相一致的财务报告。2007年，他在特拉维夫大学（Tel Aviv University）获得金融工商管理硕士学位；1999年，在The College for Management获得工商管理和会计学学士学位，目前是以色列的一名注册会计师。他已经从公司辞职，于2011年3月31日生效。
- Assaf Itshayek has served as our Chief Financial Officer since January 2010. Mr. Itshayek was formerly our Vice President of Finance, which position he held since joining the Company in June 2009. Prior to joining the Company, Mr. Itshayek was a Corporate Controller at Metalink Ltd. in Israel, a NASDAQ listed company, from 2006 through 2008 where, among other things, he prepared financial statements in conformity with United States Generally Accepted Accounting Principles ("U.S. GAAP"). Prior to that, he was a Senior Audit Manager at Deloitte Brightman Almagor & Co. Certified Public Accountants in Israel from 2005 through 2006 where, among other things, he managed and audited high-tech and industrial companies, and prepared financial statements in conformity with U.S. GAAP. Mr. Itshayaek earned a Master of Business Administration in Financial Management from Tel Aviv University in 2007 he earned a Bachelor of Arts in Business Administration and Accountancy from The College for Management in 1999 and he is currently a licensed Certified Public Accountant in Israel. Mr. Itshayek has resigned from the Company, effective March 31 2011.
- Leon Recanati
-
Leon Recanati，2005年5月起担任本公司董事，2013年3月7日起，担任董事长。他现任Evogene Ltd.的董事，这是一个在特拉维夫证券交易所和纽约证券交易所上市的植物基因组公司。他还担任以下私营公司的董事：GlenRock Israel Ltd.、GlenRock Medical、Shellcase、Gov、Govli Financial Services Ltd.、Govli Limited、Microbes Inc.、RelTech Holdings Ltd.、Legov Ltd.、Insight Capital Ltd.、Shavit Capital Fund 和 Newbank Ltd.他曾经担任以下公司的首席执行官和/或董事长：IDB Holding Corporation、Clal Industries Ltd.、Azorim Investment Development and Construction Co Ltd.、Delek Israel Fuel Corporation 和 Super-Sol Ltd.。他曾创办Clal Biotechnologies Industries，这是在以色列开展业务的生物技术投资公司。他获得了Hebrew University of Jerusalem的工商管理硕士学位、Technion Institute of Technology和Tel Aviv University的名誉博士学位。
Leon Recanati has served on board of directors since May 2005, as the Chairman of board of directors from March 2013 to August 2020 and served as the Chairman of Compensation Committee from February 2019 until September 2023. Mr. Recanati currently serves as the Chairman of MadaTech, National Meum of Science Technology and Space in memory of Daniel and Mathilde Recanati. Mr. Recanati also serves as a member of the board of directors of Evogene Ltd., a computational biology and chemistry company listed on the TASE and New York Stock Exchange, and as a member of the board of directors of PV Nano Cell Ltd., a company traded on the OTC Market. Mr. Recanati is also a board member of the following private companies: GlenRock Israel Ltd., Gov, RelTech Holdings Ltd., Legov Ltd., Insight Capital Ltd., Shavit Capital Funds and Ofil Ltd. Mr. Recanati currently serves as the Chairman and Chief Executive Officer of GlenRock. Previoly, Mr. Recanati was Chief Executive Officer and/or Chairman of IDB Holding Corporation Ltd., Clal Indtries Ltd., Azorim Investment Development and Construction Co Ltd., Delek Israel Fuel Corporation and Super Sol Ltd. Mr. Recanati also founded Clal Biotechnologies Indtries Ltd., a biotechnology investment company operating in Israel. Mr. Recanati holds an M.B.A. degree from the Hebrew University of Jeralem and Honorary Doctorates from the Technion — Israel Institute of Technology and Tel Aviv University. - Leon Recanati，2005年5月起担任本公司董事，2013年3月7日起，担任董事长。他现任Evogene Ltd.的董事，这是一个在特拉维夫证券交易所和纽约证券交易所上市的植物基因组公司。他还担任以下私营公司的董事：GlenRock Israel Ltd.、GlenRock Medical、Shellcase、Gov、Govli Financial Services Ltd.、Govli Limited、Microbes Inc.、RelTech Holdings Ltd.、Legov Ltd.、Insight Capital Ltd.、Shavit Capital Fund 和 Newbank Ltd.他曾经担任以下公司的首席执行官和/或董事长：IDB Holding Corporation、Clal Industries Ltd.、Azorim Investment Development and Construction Co Ltd.、Delek Israel Fuel Corporation 和 Super-Sol Ltd.。他曾创办Clal Biotechnologies Industries，这是在以色列开展业务的生物技术投资公司。他获得了Hebrew University of Jerusalem的工商管理硕士学位、Technion Institute of Technology和Tel Aviv University的名誉博士学位。
- Leon Recanati has served on board of directors since May 2005, as the Chairman of board of directors from March 2013 to August 2020 and served as the Chairman of Compensation Committee from February 2019 until September 2023. Mr. Recanati currently serves as the Chairman of MadaTech, National Meum of Science Technology and Space in memory of Daniel and Mathilde Recanati. Mr. Recanati also serves as a member of the board of directors of Evogene Ltd., a computational biology and chemistry company listed on the TASE and New York Stock Exchange, and as a member of the board of directors of PV Nano Cell Ltd., a company traded on the OTC Market. Mr. Recanati is also a board member of the following private companies: GlenRock Israel Ltd., Gov, RelTech Holdings Ltd., Legov Ltd., Insight Capital Ltd., Shavit Capital Funds and Ofil Ltd. Mr. Recanati currently serves as the Chairman and Chief Executive Officer of GlenRock. Previoly, Mr. Recanati was Chief Executive Officer and/or Chairman of IDB Holding Corporation Ltd., Clal Indtries Ltd., Azorim Investment Development and Construction Co Ltd., Delek Israel Fuel Corporation and Super Sol Ltd. Mr. Recanati also founded Clal Biotechnologies Indtries Ltd., a biotechnology investment company operating in Israel. Mr. Recanati holds an M.B.A. degree from the Hebrew University of Jeralem and Honorary Doctorates from the Technion — Israel Institute of Technology and Tel Aviv University.
- Ishay Davidi
-
Ishay Davidi，自2012年12月31日担任公司董事。自1996年起担任FIMI Opportunity 基金（以色列最大的私募股权基金集团）创始人和首席执行官。现任Inrom Industries有限公司、Ormat Industries 有限公司、TASE and Ham-Let （Israel-Canada）有限公司、（TASE）， C. Mer有限公司、（TASE）， Pharm Up有限公司和Overseas Commerce 有限公司董事。他之前从2008年8月到2010年1月担任Retalix（之前在纳斯达克证券交易所和特拉维夫证券交易所上市）董事长 ；Tefron有限公司（纽约证券交易所和特拉维夫证券交易所上市）以及 Tadir-Gan公司（特拉维夫证券交易所上市）董事长；以及 Retalix, Tadiran Communicationsof Tefron Ltd.公司（特拉维夫证券交易所上市）、Merhav Ceramic and Building Materials Center Ltd.公司（特拉维夫证券交易所上市）、TAT Technologies Ltd. 公司（纳斯达克证券交易所和特拉维夫证券交易所上市）、 Orian C.M. Ltd.公司（特拉维夫证券交易所上市）、 Ophir Optronics Ltd.公司（特拉维夫证券交易所上市）、Scope Metals Group Ltd.公司（特拉维夫证券交易所上市）和 Formula Systems Ltd.公司（纳斯达克证券交易所和特拉维夫证券交易所上市）董事。创立 FIMI之前，从1993年到1996年他是Tikvah基金（以色列一家私人投资基金）的创始人和首席执行官。从1992年到1993年担任Zer Science Industries有限公司（医疗行业诊断设备的开发商）首席执行官。他持有以色列特拉维夫大学工业和工程管理学士学位以及以色列巴伊兰大学工商管理硕士学位。
Ishay Davidi has served on board of directors since December 2019. Mr. Davidi is the Founder and has served as Chief Executive Officer of the FIMI Opportunity Funds, Israel's largest group of private equity funds, since 1996. Mr. Davidi currently serves as the Chairman of the Board of Directors of Polyram Plastic Indtries Ltd. (TASE), Ashot Ashkelon Indtries Ltd. (TASE), and Bio Lab Ltd. Mr. Davidi also serves as a director of Bet Shemesh Engines Ltd. (TASE), C. Mer Indtries Ltd. (TASE), PCB Technologies Ltd. (TASE), Rekah Pharmaceutical Indtries (TASE), SOS Ltd., GreenStream Ltd., Amiad Water Systems Ltd. (AIM), Rimoni Indtries Ltd. (TASE), Elyakim Ben Ari Group Ltd., Amal and Beyond Ltd., Carmex Precision Tolls Ltd. and Gat Fertilizers Ltd. Mr. Davidi previoly served as the Chairman of the board of directors of Infinya Ltd. (TASE), Inrom, Retalix (previoly traded on NASDAQ and TASE) and Tefron Ltd. (NYSE and TASE) and as a director of Gilat Satellite Networks Ltd. (NASDAQ and TASE), Pharm Up Ltd (TASE), Ham Let Ltd. (TASE), Ormat Indtries Ltd. (previoly traded on TASE), Lipman Electronic Engineering Ltd. (NASDAQ and TASE), Merhav Ceramic and Building Materials Center Ltd. (NASDAQ and TASE), Orian C.M. Ltd. (TASE), Ophir Optronics Ltd., Overseas Commerce Ltd. (TASE), Scope Metals Group Ltd. (TASE), Tadir Gan (Precision Products) 1993 Ltd. (TASE) and Formula Systems Ltd. (NASDAQ and TASE). Prior to establishing FIMI, from 1993 until 1996, Mr. Davidi was the Founder and Chief Executive Officer of Tikvah Fund, a private Israeli investment fund. From 1992 until 1993 Mr. Davidi served as the Chief Executive Officer of Zer Science Indtries Ltd. Mr. Davidi holds an M.B.A. degree from Bar Ilan University, Israel, and a B.Sc. degree, with honors, in Indtrial Engineering from the Tel Aviv University, Israel. - Ishay Davidi，自2012年12月31日担任公司董事。自1996年起担任FIMI Opportunity 基金（以色列最大的私募股权基金集团）创始人和首席执行官。现任Inrom Industries有限公司、Ormat Industries 有限公司、TASE and Ham-Let （Israel-Canada）有限公司、（TASE）， C. Mer有限公司、（TASE）， Pharm Up有限公司和Overseas Commerce 有限公司董事。他之前从2008年8月到2010年1月担任Retalix（之前在纳斯达克证券交易所和特拉维夫证券交易所上市）董事长 ；Tefron有限公司（纽约证券交易所和特拉维夫证券交易所上市）以及 Tadir-Gan公司（特拉维夫证券交易所上市）董事长；以及 Retalix, Tadiran Communicationsof Tefron Ltd.公司（特拉维夫证券交易所上市）、Merhav Ceramic and Building Materials Center Ltd.公司（特拉维夫证券交易所上市）、TAT Technologies Ltd. 公司（纳斯达克证券交易所和特拉维夫证券交易所上市）、 Orian C.M. Ltd.公司（特拉维夫证券交易所上市）、 Ophir Optronics Ltd.公司（特拉维夫证券交易所上市）、Scope Metals Group Ltd.公司（特拉维夫证券交易所上市）和 Formula Systems Ltd.公司（纳斯达克证券交易所和特拉维夫证券交易所上市）董事。创立 FIMI之前，从1993年到1996年他是Tikvah基金（以色列一家私人投资基金）的创始人和首席执行官。从1992年到1993年担任Zer Science Industries有限公司（医疗行业诊断设备的开发商）首席执行官。他持有以色列特拉维夫大学工业和工程管理学士学位以及以色列巴伊兰大学工商管理硕士学位。
- Ishay Davidi has served on board of directors since December 2019. Mr. Davidi is the Founder and has served as Chief Executive Officer of the FIMI Opportunity Funds, Israel's largest group of private equity funds, since 1996. Mr. Davidi currently serves as the Chairman of the Board of Directors of Polyram Plastic Indtries Ltd. (TASE), Ashot Ashkelon Indtries Ltd. (TASE), and Bio Lab Ltd. Mr. Davidi also serves as a director of Bet Shemesh Engines Ltd. (TASE), C. Mer Indtries Ltd. (TASE), PCB Technologies Ltd. (TASE), Rekah Pharmaceutical Indtries (TASE), SOS Ltd., GreenStream Ltd., Amiad Water Systems Ltd. (AIM), Rimoni Indtries Ltd. (TASE), Elyakim Ben Ari Group Ltd., Amal and Beyond Ltd., Carmex Precision Tolls Ltd. and Gat Fertilizers Ltd. Mr. Davidi previoly served as the Chairman of the board of directors of Infinya Ltd. (TASE), Inrom, Retalix (previoly traded on NASDAQ and TASE) and Tefron Ltd. (NYSE and TASE) and as a director of Gilat Satellite Networks Ltd. (NASDAQ and TASE), Pharm Up Ltd (TASE), Ham Let Ltd. (TASE), Ormat Indtries Ltd. (previoly traded on TASE), Lipman Electronic Engineering Ltd. (NASDAQ and TASE), Merhav Ceramic and Building Materials Center Ltd. (NASDAQ and TASE), Orian C.M. Ltd. (TASE), Ophir Optronics Ltd., Overseas Commerce Ltd. (TASE), Scope Metals Group Ltd. (TASE), Tadir Gan (Precision Products) 1993 Ltd. (TASE) and Formula Systems Ltd. (NASDAQ and TASE). Prior to establishing FIMI, from 1993 until 1996, Mr. Davidi was the Founder and Chief Executive Officer of Tikvah Fund, a private Israeli investment fund. From 1992 until 1993 Mr. Davidi served as the Chief Executive Officer of Zer Science Indtries Ltd. Mr. Davidi holds an M.B.A. degree from Bar Ilan University, Israel, and a B.Sc. degree, with honors, in Indtrial Engineering from the Tel Aviv University, Israel.
高管简历
中英对照 | 中文 | 英文- Yael Brenner
Yael Brenner自2015年3月起担任副总裁，质量。Brenner女士在质量管理方面拥有超过25年的经验，包括在制药工业的质量保证和质量控制管理职位。在加入Kamada之前，2007年至2015年，Brenner女士在Teva Pharmaceuticals Indtries任职，最后担任Teva Kfar Sava工厂质量运营高级总监，在质量保证、质量控制和法规事务方面管理着400多名员工。Brenner女士拥有以色列理工学院化学学士和理学硕士学位，她是美国和以色列质量学会的认证质量工程师（CQE）。
Yael Brenner has served as Vice President, Quality since March 2015. Ms. Brenner has more than 25 years of experience in Quality Management, including Quality Assurance and Quality Control managerial positions in the pharmaceutical indtry. Prior to joining Kamada, from 2007 to 2015, Ms. Brenner was at Teva Pharmaceuticals Indtries, lastly as Senior Director Quality Operations of Teva's Kfar Sava Site, managing over 400 employees in Quality Assurance, Quality Control and Regulatory Affairs. Ms. Brenner holds B.Sc. and M.Sc. degrees in Chemistry from the Technion Israel Institute of Technology, and she is a Certified Quality Engineer (CQE) from the American and Israeli Societies for Quality.- Yael Brenner自2015年3月起担任副总裁，质量。Brenner女士在质量管理方面拥有超过25年的经验，包括在制药工业的质量保证和质量控制管理职位。在加入Kamada之前，2007年至2015年，Brenner女士在Teva Pharmaceuticals Indtries任职，最后担任Teva Kfar Sava工厂质量运营高级总监，在质量保证、质量控制和法规事务方面管理着400多名员工。Brenner女士拥有以色列理工学院化学学士和理学硕士学位，她是美国和以色列质量学会的认证质量工程师（CQE）。
- Yael Brenner has served as Vice President, Quality since March 2015. Ms. Brenner has more than 25 years of experience in Quality Management, including Quality Assurance and Quality Control managerial positions in the pharmaceutical indtry. Prior to joining Kamada, from 2007 to 2015, Ms. Brenner was at Teva Pharmaceuticals Indtries, lastly as Senior Director Quality Operations of Teva's Kfar Sava Site, managing over 400 employees in Quality Assurance, Quality Control and Regulatory Affairs. Ms. Brenner holds B.Sc. and M.Sc. degrees in Chemistry from the Technion Israel Institute of Technology, and she is a Certified Quality Engineer (CQE) from the American and Israeli Societies for Quality.
- Orit Pinchuk
Orit Pinchuk，2014年10月起担任本公司监管事务和质量研发副总裁。有着超过20年的医药行业经验，制造包括法规事务和法规遵从。加入Kamada前，曾于1993-2014年期间，在Teva Pharmaceuticals Industries工作，担任合规与监管事务、以色列事务总监，以色列监管事务、研发总监。有着丰富的FDA, EMA and CANADA Health Authorities经验。持有Shenkar学院的纺织化学学位，修工程和设计专业；以及耶路撒冷Hebrew大学的应用化学硕士学位。
Orit Pinchuk has served as Vice President of Regulatory Affairs and PVG since October 2014. Ms. Pinchuk has over 30 years of experience in the pharmaceutical indtry, holding senior roles across Regulatory Affairs and Compliance. Prior to joining Kamada, Ms. Pinchuk served more than two decades at Teva Pharmaceuticals Indtries (1993 2014), where she served as Director of Compliance and Regulatory Affairs, Operation Israel and Senior Director of Regulatory Affairs, Research and Development and Operation Israel. Ms. Pinchuk has extensive experience collaborating with global health authorities, including the FDA, EMA and the Canadian health authority. Ms. Pinchuk holds a B.Tech degree in Textile Chemistry from Shenkar College for Engineering and Design and M.Sc. degree in Applied Chemistry from the Hebrew University of Jeralem.- Orit Pinchuk，2014年10月起担任本公司监管事务和质量研发副总裁。有着超过20年的医药行业经验，制造包括法规事务和法规遵从。加入Kamada前，曾于1993-2014年期间，在Teva Pharmaceuticals Industries工作，担任合规与监管事务、以色列事务总监，以色列监管事务、研发总监。有着丰富的FDA, EMA and CANADA Health Authorities经验。持有Shenkar学院的纺织化学学位，修工程和设计专业；以及耶路撒冷Hebrew大学的应用化学硕士学位。
- Orit Pinchuk has served as Vice President of Regulatory Affairs and PVG since October 2014. Ms. Pinchuk has over 30 years of experience in the pharmaceutical indtry, holding senior roles across Regulatory Affairs and Compliance. Prior to joining Kamada, Ms. Pinchuk served more than two decades at Teva Pharmaceuticals Indtries (1993 2014), where she served as Director of Compliance and Regulatory Affairs, Operation Israel and Senior Director of Regulatory Affairs, Research and Development and Operation Israel. Ms. Pinchuk has extensive experience collaborating with global health authorities, including the FDA, EMA and the Canadian health authority. Ms. Pinchuk holds a B.Tech degree in Textile Chemistry from Shenkar College for Engineering and Design and M.Sc. degree in Applied Chemistry from the Hebrew University of Jeralem.
- Chaime Orlev
Chaime Orlev自2011年12月起担任公司财务和行政副总裁。他在2010年6月加入公司担任财务董事。在加入公司之前（2008-2010年），他是几家以色列（Israel）生物技术和医疗设备公司的财务顾问。2008-2009年他担任Oramed Pharmaceuticals股份有限公司（Oramed Pharmaceuticals Inc）的财务总监；2005-2008年他担任Gammacan International股份有限公司（Gammacan International Inc.）的财务总监；2001-2004年担任Huntleigh财务副总裁和财务总监。Orlev先生取得特拉维夫大学（Tel Aviv University）商业管理Leon Recanati研究生院的工商管理硕士学位。他是以色列（Israel）法律的一名注册会计师。
Chaime Orlev has served as Chief Financial Officer since December 2017. Prior to that, Mr. Orlev had served in senior finance roles for more than 20 years, with approximately 13 years spent in the life sciences indtry. Previoly, from September 2016 to November 2017, Mr. Orlev served as Chief Financial Officer and Vice President Finance and Administration at Bioblast Pharma Ltd. (Nasdaq: ORPN), a clinical stage, biotechnology company. Prior to that, from 2010, Mr. Orlev served as Vice President Finance and Administration at Chiasma (Nasdaq: CHMA), a clinical stage biopharmaceutical company, in which role Mr. Orlev led the company's initial public offering and listing on Nasdaq. Mr. Orlev holds a BA degree in Biness Administration from the College of Management in Israel, an MBA degree from the Recanati Graduate School of Biness Administration at the Tel Aviv University and is a certified public accountant in Israel.- Chaime Orlev自2011年12月起担任公司财务和行政副总裁。他在2010年6月加入公司担任财务董事。在加入公司之前（2008-2010年），他是几家以色列（Israel）生物技术和医疗设备公司的财务顾问。2008-2009年他担任Oramed Pharmaceuticals股份有限公司（Oramed Pharmaceuticals Inc）的财务总监；2005-2008年他担任Gammacan International股份有限公司（Gammacan International Inc.）的财务总监；2001-2004年担任Huntleigh财务副总裁和财务总监。Orlev先生取得特拉维夫大学（Tel Aviv University）商业管理Leon Recanati研究生院的工商管理硕士学位。他是以色列（Israel）法律的一名注册会计师。
- Chaime Orlev has served as Chief Financial Officer since December 2017. Prior to that, Mr. Orlev had served in senior finance roles for more than 20 years, with approximately 13 years spent in the life sciences indtry. Previoly, from September 2016 to November 2017, Mr. Orlev served as Chief Financial Officer and Vice President Finance and Administration at Bioblast Pharma Ltd. (Nasdaq: ORPN), a clinical stage, biotechnology company. Prior to that, from 2010, Mr. Orlev served as Vice President Finance and Administration at Chiasma (Nasdaq: CHMA), a clinical stage biopharmaceutical company, in which role Mr. Orlev led the company's initial public offering and listing on Nasdaq. Mr. Orlev holds a BA degree in Biness Administration from the College of Management in Israel, an MBA degree from the Recanati Graduate School of Biness Administration at the Tel Aviv University and is a certified public accountant in Israel.
- Eran Nir
Eran Nir自2016年11月1日起担任我们的运营Vice President。Nir先生在制药和医疗行业拥有超过14年的运营管理经验。Nir先生最近的职务包括2002年至2011年管理Teva&8217；s在耶路撒冷的制药厂，2014年至2015年担任Amelia Cosmetics的运营副总裁，2015年至2016年管理Philips Medical Systems的医疗设备厂。Nir’；先生的丰富经验横跨大型FDA和EMA批准的制造设施的管理，新产品从开发到生产的技术转移以及世界级卓越运营系统的实施。Nir先生拥有学士学位。Ben-Gurion University工业和管理工程学位以及工商管理硕士学位。
Eran Nir has served as Chief Operating Officer since March 2022, overseeing operations and research and development activities. Prior to that Mr. Nir served as Vice President, Operations from November 2016. Mr. Nir has over 20 years of operations management experience in the pharmaceutical and medical indtries. Mr. Nir's previo roles include management of Teva Pharmaceutical Indtries' plant in Jeralem from 2002 to 2011, VP Operations of Amelia Cosmetics from 2014 to 2015 and management of a medical equipment plant of Philips Medical Systems from 2015 to 2016. Mr. Nir's experience spans across the management of large scale FDA and EMA approved manufacturing facilities, tech transfer of new products from development to production and the implementation of operational excellence systems. Mr. Nir holds a B.Sc. degree in Indtrial and Management Engineering and an MBA degree, both from Ben Gurion University.- Eran Nir自2016年11月1日起担任我们的运营Vice President。Nir先生在制药和医疗行业拥有超过14年的运营管理经验。Nir先生最近的职务包括2002年至2011年管理Teva&8217；s在耶路撒冷的制药厂，2014年至2015年担任Amelia Cosmetics的运营副总裁，2015年至2016年管理Philips Medical Systems的医疗设备厂。Nir’；先生的丰富经验横跨大型FDA和EMA批准的制造设施的管理，新产品从开发到生产的技术转移以及世界级卓越运营系统的实施。Nir先生拥有学士学位。Ben-Gurion University工业和管理工程学位以及工商管理硕士学位。
- Eran Nir has served as Chief Operating Officer since March 2022, overseeing operations and research and development activities. Prior to that Mr. Nir served as Vice President, Operations from November 2016. Mr. Nir has over 20 years of operations management experience in the pharmaceutical and medical indtries. Mr. Nir's previo roles include management of Teva Pharmaceutical Indtries' plant in Jeralem from 2002 to 2011, VP Operations of Amelia Cosmetics from 2014 to 2015 and management of a medical equipment plant of Philips Medical Systems from 2015 to 2016. Mr. Nir's experience spans across the management of large scale FDA and EMA approved manufacturing facilities, tech transfer of new products from development to production and the implementation of operational excellence systems. Mr. Nir holds a B.Sc. degree in Indtrial and Management Engineering and an MBA degree, both from Ben Gurion University.
- Liron Reshef
Liron Reshef于2018年10月被任命为TAT&；8217；S执行副总裁。在加入TAT之前，Reshef女士于2014年至2018年担任生物技术公司Evogene的人力资源副总裁，该公司在特拉维夫和纳斯达克上市。从2012年到2013年，Reshef女士担任Frutarom的全球人力资源总监，这是一家总部位于以色列的全球领先的食品行业公司。从2007年到2012年，Reshef女士担任Solbar Industries的人力资源副总裁，这是一家在特拉维夫上市的食品和制药行业的公司。在此之前，Reshef女士在多家高科技公司担任了10多年的执行人力资源职位，Reshef女士拥有Bar-Ilan University的经济学和政治学学士学位，以及Ben-Gurion University的管理行为科学工商管理硕士学位。
Liron Reshef was appointed as TAT’s EVP Human Resources in October 2018. Prior to joining TAT, from 2014 to 2018 Ms. Reshef served as VP Human Resources at Evogene, a bio-tech company, listed in Tel Aviv and Nasdaq. From 2012 until 2013 Ms. Reshef served as Global HR Director for Frutarom, a leading global Israeli based company specializes food industry. From 2007 until 2012 Ms. Reshef served as a VP Human Recourses in Solbar Industries, a company in the food and pharmaceutical industry listed in Tel Aviv. Prior to that, Ms. Reshef served, for over 10 years, in executive Human Resources positions at various hi-tech companies Ms. Reshef holds a B.A. in Economics and Political Science from Bar-Ilan University and MBA -specialization in managing behavioral sciences from Ben-Gurion University.- Liron Reshef于2018年10月被任命为TAT&；8217；S执行副总裁。在加入TAT之前，Reshef女士于2014年至2018年担任生物技术公司Evogene的人力资源副总裁，该公司在特拉维夫和纳斯达克上市。从2012年到2013年，Reshef女士担任Frutarom的全球人力资源总监，这是一家总部位于以色列的全球领先的食品行业公司。从2007年到2012年，Reshef女士担任Solbar Industries的人力资源副总裁，这是一家在特拉维夫上市的食品和制药行业的公司。在此之前，Reshef女士在多家高科技公司担任了10多年的执行人力资源职位，Reshef女士拥有Bar-Ilan University的经济学和政治学学士学位，以及Ben-Gurion University的管理行为科学工商管理硕士学位。
- Liron Reshef was appointed as TAT’s EVP Human Resources in October 2018. Prior to joining TAT, from 2014 to 2018 Ms. Reshef served as VP Human Resources at Evogene, a bio-tech company, listed in Tel Aviv and Nasdaq. From 2012 until 2013 Ms. Reshef served as Global HR Director for Frutarom, a leading global Israeli based company specializes food industry. From 2007 until 2012 Ms. Reshef served as a VP Human Recourses in Solbar Industries, a company in the food and pharmaceutical industry listed in Tel Aviv. Prior to that, Ms. Reshef served, for over 10 years, in executive Human Resources positions at various hi-tech companies Ms. Reshef holds a B.A. in Economics and Political Science from Bar-Ilan University and MBA -specialization in managing behavioral sciences from Ben-Gurion University.
- Hanni Neheman
Hanni Neheman自2020年1月起担任我们的Vice President，营销和销售。Neheman女士于2014年8月加入我们，并担任以色列业务运营主管。Neheman女士在制药行业市场营销与销售领域的不同职位上拥有超过20年的专业知识。在加入我们之前，Neheman女士曾担任Neopharm Israel的商业经理。Neheman女士拥有以色列理工学院（Technion Israel Institute of Technology）的职业疗法学士学位和德比大学（Derby University）的执行工商管理硕士学位。
Hanni Neheman has served as Vice President, Marketing & Sales since January 2020. Ms. Neheman joined in Augt 2014 and served as Head of Biness Operations, Israel. Ms. Neheman has more than 20 years of experience in different positions in the field of marketing and sales in the pharmaceutical indtry. Prior to joining , Ms. Neheman served as a Commercial Manager at Neopharm Israel. Ms. Neheman holds a B.A. degree in Occupational Therapy from the Technion Israel Institute of Technology and Executive M.B.A degree from Derby University.- Hanni Neheman自2020年1月起担任我们的Vice President，营销和销售。Neheman女士于2014年8月加入我们，并担任以色列业务运营主管。Neheman女士在制药行业市场营销与销售领域的不同职位上拥有超过20年的专业知识。在加入我们之前，Neheman女士曾担任Neopharm Israel的商业经理。Neheman女士拥有以色列理工学院（Technion Israel Institute of Technology）的职业疗法学士学位和德比大学（Derby University）的执行工商管理硕士学位。
- Hanni Neheman has served as Vice President, Marketing & Sales since January 2020. Ms. Neheman joined in Augt 2014 and served as Head of Biness Operations, Israel. Ms. Neheman has more than 20 years of experience in different positions in the field of marketing and sales in the pharmaceutical indtry. Prior to joining , Ms. Neheman served as a Commercial Manager at Neopharm Israel. Ms. Neheman holds a B.A. degree in Occupational Therapy from the Technion Israel Institute of Technology and Executive M.B.A degree from Derby University.
- Boris Gorelik
Boris Gorelik自2022年6月起担任BINSE发展和战略项目副总裁。在此之前，Gorelik先生自2020年4月起担任BINEY Development董事。Gorelik先生拥有超过15年的BINCE开发和并购经验，其中大部分在制药行业。在加入之前，Gorelik先生是梯瓦制药 Indtries，Ltd.的全球Biness发展和战略高级总监。在加入Teva之前，Gorelik先生曾在Goldfarb Seligman的以色列律师事务所担任多个法律、并购和交易服务相关职务，还曾担任毕马威和德勤以色列办事处的职务。Gorelik先生拥有法学学士学位、会计学学士学位和MBA学位，均来自特拉维夫大学。
Boris Gorelik has served as Vice President, Biness Development and Strategic Programs since June 2022. Prior to that, Mr. Gorelik served as Director of Biness Development from April 2020. Mr. Gorelik has over 15 years of Biness Development and M&A experience, most of it in the pharmaceutical industry. Prior to joining , Mr. Gorelik was Senior Director of Global Biness Development and Strategy with Teva Pharmaceutical Indtries, Ltd. Prior to his tenure at Teva, Mr. Gorelik served in vario legal, M&A, and transaction services related roles in the Israeli law office of Goldfarb Seligman, as ll as KPMG and Deloitte Israeli offices. Mr. Gorelik holds a LL.B. degree, B.A. degree in Accounting and MBA degree, all from Tel Aviv University.- Boris Gorelik自2022年6月起担任BINSE发展和战略项目副总裁。在此之前，Gorelik先生自2020年4月起担任BINEY Development董事。Gorelik先生拥有超过15年的BINCE开发和并购经验，其中大部分在制药行业。在加入之前，Gorelik先生是梯瓦制药 Indtries，Ltd.的全球Biness发展和战略高级总监。在加入Teva之前，Gorelik先生曾在Goldfarb Seligman的以色列律师事务所担任多个法律、并购和交易服务相关职务，还曾担任毕马威和德勤以色列办事处的职务。Gorelik先生拥有法学学士学位、会计学学士学位和MBA学位，均来自特拉维夫大学。
- Boris Gorelik has served as Vice President, Biness Development and Strategic Programs since June 2022. Prior to that, Mr. Gorelik served as Director of Biness Development from April 2020. Mr. Gorelik has over 15 years of Biness Development and M&A experience, most of it in the pharmaceutical industry. Prior to joining , Mr. Gorelik was Senior Director of Global Biness Development and Strategy with Teva Pharmaceutical Indtries, Ltd. Prior to his tenure at Teva, Mr. Gorelik served in vario legal, M&A, and transaction services related roles in the Israeli law office of Goldfarb Seligman, as ll as KPMG and Deloitte Israeli offices. Mr. Gorelik holds a LL.B. degree, B.A. degree in Accounting and MBA degree, all from Tel Aviv University.
- Nir Livneh
Nir Livneh自2023年4月起担任副总裁总法律顾问和公司秘书。Livneh previoly先生自2010年至2018年担任总法律顾问和公司秘书。在重新加入Kamada之前，Livneh先生曾担任Purple Biotech Ltd. Previoly的法律事务副总裁，Livneh先生曾担任ICL Group Ltd.的法律顾问和PolyPid Ltd.的总法律顾问。Livneh先生是Israel Bar协会的成员并持有法学学士学位。（法学学士）和以色列荷兹利亚Reichman大学BINCE Administration学士学位，以色列特拉维夫大学法学硕士学位。
Nir Livneh has served as VP General Counsel and Corporate Secretary since April 2023. Mr. Livneh previoly served as General Counsel and Corporate Secretary, from 2010 2018. Prior to rejoining Kamada, Mr. Livneh served as Vice President of Legal Affairs at Purple Biotech Ltd. Previoly, Mr. Livneh served as Legal Counsel at ICL Group Ltd. and General Counsel of PolyPid Ltd. Mr. Livneh is a member of the Israel Bar Association and holds an LL.B. (Bachelor of Law) and a B.A. degree in Biness Administration from the Reichman University, Herzliya, Israel, and an LL.M degree from Tel Aviv University, Israel.- Nir Livneh自2023年4月起担任副总裁总法律顾问和公司秘书。Livneh previoly先生自2010年至2018年担任总法律顾问和公司秘书。在重新加入Kamada之前，Livneh先生曾担任Purple Biotech Ltd. Previoly的法律事务副总裁，Livneh先生曾担任ICL Group Ltd.的法律顾问和PolyPid Ltd.的总法律顾问。Livneh先生是Israel Bar协会的成员并持有法学学士学位。（法学学士）和以色列荷兹利亚Reichman大学BINCE Administration学士学位，以色列特拉维夫大学法学硕士学位。
- Nir Livneh has served as VP General Counsel and Corporate Secretary since April 2023. Mr. Livneh previoly served as General Counsel and Corporate Secretary, from 2010 2018. Prior to rejoining Kamada, Mr. Livneh served as Vice President of Legal Affairs at Purple Biotech Ltd. Previoly, Mr. Livneh served as Legal Counsel at ICL Group Ltd. and General Counsel of PolyPid Ltd. Mr. Livneh is a member of the Israel Bar Association and holds an LL.B. (Bachelor of Law) and a B.A. degree in Biness Administration from the Reichman University, Herzliya, Israel, and an LL.M degree from Tel Aviv University, Israel.
- Shavit Beladev
Shavit Beladev自2022年6月起担任等离子体运营副总裁。Beladev女士已在越来越高级的职位上工作了20多年，最近担任BINCE Development的董事。Beladev previoly女士担任管理职务，负责国际销售、大客户管理和等离子采购。自2021年初成立Kamada Plasma以来，Beladev女士的延伸职责还包括通过其美国子公司Kamada Plasma LLC监督公司的血浆采集业务。Beladev女士拥有以色列本古里安大学经济学和BINES行政管理学士学位。
Shavit Beladev has served as Vice President, Plasma Operations since June 2022. Ms. Beladev has been with for over 20 years in increasingly senior positions, most recently as Director of Biness Development. Ms. Beladev previoly served in management roles responsible for International Sales, Key Accounts Management and Plasma Procurement. Since the establishment of Kamada Plasma in early 2021, Ms. Beladev's extended responsibilities have also included overseeing the Company's plasma collection operations through its U.S. subsidiary Kamada Plasma LLC. Ms. Beladev holds a B.A. degree in Economics and Biness Administration from Ben Gurion University, Israel.- Shavit Beladev自2022年6月起担任等离子体运营副总裁。Beladev女士已在越来越高级的职位上工作了20多年，最近担任BINCE Development的董事。Beladev previoly女士担任管理职务，负责国际销售、大客户管理和等离子采购。自2021年初成立Kamada Plasma以来，Beladev女士的延伸职责还包括通过其美国子公司Kamada Plasma LLC监督公司的血浆采集业务。Beladev女士拥有以色列本古里安大学经济学和BINES行政管理学士学位。
- Shavit Beladev has served as Vice President, Plasma Operations since June 2022. Ms. Beladev has been with for over 20 years in increasingly senior positions, most recently as Director of Biness Development. Ms. Beladev previoly served in management roles responsible for International Sales, Key Accounts Management and Plasma Procurement. Since the establishment of Kamada Plasma in early 2021, Ms. Beladev's extended responsibilities have also included overseeing the Company's plasma collection operations through its U.S. subsidiary Kamada Plasma LLC. Ms. Beladev holds a B.A. degree in Economics and Biness Administration from Ben Gurion University, Israel.
- Jon Knight
Jon Knight自2022年3月起担任商业运营副总裁。Knight先生拥有超过25年的生命科学经验，主要专注于将创新的特种等离子产品商业化。在加入之前，奈特曾担任过多个商业领导职位。Previoly Mr. Knight在TherapeuticsMD负责贸易关系，向美国市场推出了三款创新产品。Knight先生的专业背景还包括在Prometic Life Sciences、CIS by Deloitte、卡地纳健康、Cangene BioPharma和Nabi BioPharmaceuticals担任领导职务。Knight先生拥有科罗拉多州立大学MBA学位和科罗拉多梅萨大学生物学学士学位。
Jon Knight has served as Vice President of Commercial Operations since March 2022. Mr. Knight has over 25 years of Life Sciences experience, primarily focing on commercializing innovative specialty plasma products. Prior to joining , Mr. Knight served in a variety of commercial leadership positions. Previoly Mr. Knight was responsible for Trade Relations at TherapeuticsMD, launching three innovative products into the U.S. market. Mr. Knight's professional background also includes leadership positions at Prometic Life Sciences, CIS by Deloitte, Cardinal Health, Cangene BioPharma and Nabi Biopharmaceuticals. Mr. Knight holds an MBA degree from Colorado State University and a B.A. degree in Biology from Colorado Mesa University.- Jon Knight自2022年3月起担任商业运营副总裁。Knight先生拥有超过25年的生命科学经验，主要专注于将创新的特种等离子产品商业化。在加入之前，奈特曾担任过多个商业领导职位。Previoly Mr. Knight在TherapeuticsMD负责贸易关系，向美国市场推出了三款创新产品。Knight先生的专业背景还包括在Prometic Life Sciences、CIS by Deloitte、卡地纳健康、Cangene BioPharma和Nabi BioPharmaceuticals担任领导职务。Knight先生拥有科罗拉多州立大学MBA学位和科罗拉多梅萨大学生物学学士学位。
- Jon Knight has served as Vice President of Commercial Operations since March 2022. Mr. Knight has over 25 years of Life Sciences experience, primarily focing on commercializing innovative specialty plasma products. Prior to joining , Mr. Knight served in a variety of commercial leadership positions. Previoly Mr. Knight was responsible for Trade Relations at TherapeuticsMD, launching three innovative products into the U.S. market. Mr. Knight's professional background also includes leadership positions at Prometic Life Sciences, CIS by Deloitte, Cardinal Health, Cangene BioPharma and Nabi Biopharmaceuticals. Mr. Knight holds an MBA degree from Colorado State University and a B.A. degree in Biology from Colorado Mesa University.
- Amir London
Amir London，2013年12月起，担任本公司的业务开发高级副总裁。他带来了20多年的高级管理与国际业务开发的经验。2011-2013，他担任Fidelis Diagnostics的首席运营官，这是一家美国公司，从事提供创新的办公室内医疗诊断服务。职业生涯早期，2009-2011，他担任Promedico的首席执行官，这是营收达3.5亿美元的以色列的著名保健经销公司；2006-2009，担任Cure Medical的总经理，为临床研究和家庭护理解决方案提供承包生产服务。1995-2006，他是Tefen的合伙人，这是国际性的运营管理咨询上市公司，他负责该公司的全球生物制药业务。他获得了Technion - Israel Institute of Technology的工业与管理工程学士学位。
Amir London has served as Chief Executive Officer since July 2015. Prior to that, Mr. London served as Senior Vice President, Biness Development from December 2013. From 2011 to 2013, Mr. London served as the Chief Operating Officer of Fidelis Diagnostics, a U.S. based provider of innovative in office medical diagnostic services. Earlier in his career, from 2009 to 2011, Mr. London was the Chief Executive Officer of Promedico, an Israeli based $350 million healthcare distribution company, and from 2006 to 2009 he was the General Manager of Cure Medical, providing contract manufacturing services for clinical studies, as ll as home care solutions. From 1995 to 2006, Mr. London was a Partner with Tefen, an international publicly traded operations management consulting firm, responsible for the firm's global biopharma practice. Mr. London holds a B.Sc. degree in Indtrial and Management Engineering from the Technion – Israel Institute of Technology.- Amir London，2013年12月起，担任本公司的业务开发高级副总裁。他带来了20多年的高级管理与国际业务开发的经验。2011-2013，他担任Fidelis Diagnostics的首席运营官，这是一家美国公司，从事提供创新的办公室内医疗诊断服务。职业生涯早期，2009-2011，他担任Promedico的首席执行官，这是营收达3.5亿美元的以色列的著名保健经销公司；2006-2009，担任Cure Medical的总经理，为临床研究和家庭护理解决方案提供承包生产服务。1995-2006，他是Tefen的合伙人，这是国际性的运营管理咨询上市公司，他负责该公司的全球生物制药业务。他获得了Technion - Israel Institute of Technology的工业与管理工程学士学位。
- Amir London has served as Chief Executive Officer since July 2015. Prior to that, Mr. London served as Senior Vice President, Biness Development from December 2013. From 2011 to 2013, Mr. London served as the Chief Operating Officer of Fidelis Diagnostics, a U.S. based provider of innovative in office medical diagnostic services. Earlier in his career, from 2009 to 2011, Mr. London was the Chief Executive Officer of Promedico, an Israeli based $350 million healthcare distribution company, and from 2006 to 2009 he was the General Manager of Cure Medical, providing contract manufacturing services for clinical studies, as ll as home care solutions. From 1995 to 2006, Mr. London was a Partner with Tefen, an international publicly traded operations management consulting firm, responsible for the firm's global biopharma practice. Mr. London holds a B.Sc. degree in Indtrial and Management Engineering from the Technion – Israel Institute of Technology.